Recently, the label for the drug Dexedrine was revised to include warnings about sudden death and serious cardiovascular adverse events. Dexedrine is used to treat Attention-Deficit Hyperactivity Disorder (ADHD) and narcolepsy. GlaxoSmithKline, the manufacturer of Dexedrine, revised the drug label and sent letters to doctors at the request of the FDA. Two different advisory committees of the FDA recommended the label changes. Those changes include warnings about cardiovascular events, hypertension, psychiatric adverse events, growth suppression, seizures and vision problems.
Comments are closed.